Newsletter Signup
Where current and emerging technology trends meet.
TecTrendsInformation Sources, Inc.
  | About TecTrends | Email Signup | Contact Us
 Live Search:
Live Search | Articles | Companies | TecTerms | Products
  Loading TecTrends Live Search - please wait... 
View Noteworthy Articles      PRNewswire
 
Company

Galapagos NV Products   
Industriepark Mechelen NoordGeneraal De Wittelaan L11 A3
Mechelen,  BE  B-2800
Belgium
Telephone: (32 ) 15 34 29 00
Fax: (32) 15 34 29 01
URL: http://www.glpg.com
Email: info@glpg.com

Founded in 1999, Galapagos NV is based in Belgium with operations it several countries. It focuses on drug discovery for bone and joint diseases, cachexia, and menopausal hot flashes and also has a service division called BioFocus DPI that offers gene-to-clinical discovery services and products. The company is listed on Euronext Brussels with the symbol GLPG, Euronext Amsterdam with the symbol GLPGA, and AiM London with the symbol GLPG. Galapagos was founded as a joint venture between Crucell and Tibotec, and in 2002 became a private placement. It made its initial public offering in May 2005 and acquired the drug discovery company BioFocus in October 2005, adding Discovery Partners International (DPI) in June 2006. It also acquired Inpharmatica, another drug discovery company, and ProSkelia in December 2001. In June 2006, Galapagos entered into a broad alliance with GlaxoSmithKline to discover and develop medicines for osteoarthritis, and for that alliance Galapagos is using its patented screening programs to discover targets for drug development.

Org. Type: Corporation Equity Type: Public
Company Status: Active Date Founded: 1999

Products:
Galapagos NV--Company News

TecTerms:
 


Home About TecTrends About Us Contact Us Privacy Statement Terms and Conditions

TecTrends | P.O. Box 8120 | Berkeley CA 94707 | (510) 525-6220 | Email: tectrends@tectrends.com
© 2006 INFORMATION SOURCES INC | All rights reserved.